Prostate Cancer - Survival Rates

Doctors usually use survival rates as a standard method of discussing an individual's prognosis (outlook). Some cancer patients may not want to know the survival statistics for individuals in similar situations, while others want to find and know that statistics. If you wish to know read on.

The five-year survival rate refers to the percentage of individual's who live at least 5 years once their cancer is diagnosed. Of course, some of these individuals live much longer than five years, and many of them are cured now.

Five-year relative survival rates, such as the numbers below, assume that some individuals can die of other causes and compare the observed survival with that expected for individuals without the malignant neoplasm (cancer). This is a much better way to see the impact of the malignant neoplasm on survival.

According to the recent information, when including all men with prostate cancer:

The five-year relative survival rate is almost 100 percent

The ten-year relative survival rate is ninety eight percent

The relative 15-year survival rate is ninety one percent

Keep in mind that five-year survival rates are based on cancer patients diagnosed and first treated over five years ago, and ten year survival rates are based on cancer patients diagnosed over ten years ago. Modern ways of detection and treatment mean that a lot of prostate cancers are now found earlier and may be treated more effectively. If you're diagnosed with cancer this year, your outlook may be higher than the numbers reported above.

Survival rates by stage

The NCI(National Cancer Institute) maintains a huge national database on survival statistics for various forms of cancer. This database doesn't cluster malignant neoplasm by AJCC Cancer Staging, but instead groups malignant neoplasm into local, regional, and distant stages.

- Local stage means that there is no sign that the cancer has metastasized outside of the prostate. This corresponds to stages I and II by AJCC Cancer Staging. About four out of five prostate cancers are found during this early stage.

- Regional stage means that the cancer has metastasized from the prostate to nearby areas. This includes stage III cancers and also the}stage IV cancers that haven't metastasized to distant body parts, such as T4 tumors and cancers that have metastasized to nearby lymph nodes (N1).

- Distant stage includes the rest of the stage IV cancers – all cancers that have metastasized to bones, distant lymph nodes, or other organs (M1).

Five-year relative survival rates (%) by stage at the time of diagnosis

Stage | Five-year relative survival rate

Local Stage - nearly 100 percent
Regional Stage - nearly 100 percent
Distant Stage - twenty ninth percent

These survival rates can't predict what is going to happen in any specific man's case, and they are based on previous outcomes of huge numbers of men who had the disease.

Several other factors can have an effect on a man's outlook, like the PSA, the Gleason score, and also the man's overall health. Ask your doctor to tell you how the numbers above may apply to you, as she or he is familiar with the aspects of your specific situation.

Asbestos and Its Diseases

As you shall see with the other asbestos diseases, asbestosis was first reflected inincremental accumulation of case reports. It's perhaps difficult in retrospect to understand why the definitive discovery of the disease took 40–50 years.

Asbestos and Its Diseases

Seattle, Washington Mesothelioma Attorney - Glenn S. Draper

Washington mesothelioma attorney Glenn Draper is a partner in Bergman Draper Ladenburg law firm and he has been fighting for the rights of people against government and big companies for over a decade. Since 2004, Mr. Draper has been representing victims of mesothelioma cancer and other asbestos related diseases, becouse beyond mesothelioma cancer many disease can be caused by asbestos exposure.

“The best part of my job,” he says, “is sitting down with asbestos mesothelioma victims to figure out where they were exposed to asbestos dust and fibres, and then preparing them to testify in a way that holds those corporations responsible.”

Mr. Draper has taken the deposition of over three hundred victims of asbestos disease. Most recently, he has worked with asbestos mesothelioma victims that were exposed to products as brake materials, joint compounds, cement pipe, and insulation products. High settlement amounts were obtained in each of these asbestos cases.

Washington mesothelioma lawyer Glenn Draper has appeared in the Superior Courts for Snohomish, King, Whatcom, Pierce, Spokane, Franklin, Benton, Pacific, Jefferson, Klickitat, Chelan, Douglas, Grant, Lewis, and Thurston counties, and also in Multnomah County in Oregon.

Lawyer Glenn S. Draper grew up in a Navy family, and served many years on active duty in the U.S. Army. He was also named Soldier of the Year for the U.S. Army Support Command Hawaii.

Mr. Draper was one of several attorneys at Innocence Project Northwest that were awarded the National Law Journal’s Pro Bono Award in 2000.

By the King County Bar Association, mesothelioma attorney Glenn Draper has been recognized as a Quiet Hero for his pro bono work.

Admissions
Washington
Oregon
U.S. District Court for the Eastern District of Washington
U.S. District Court for the Western District of Washington
U.S. Supreme Court
U.S. Court of Appeals for the Ninth Circuit

Education
J.D., University of Washington, School of Law (1994)
Washington Law Review
Moot Court Honor Board
B.A Finance, University of Washington (1989)
Magna Cum Laude
Phi Beta Kappa

Publications/Speaking Engagements

Author, Enforcing Lawyers Covenants Not to Compete, Washington Law Review (1994).

Author/Speaker, Dose Reconstruction Evidence – Is it Admissible? Washington State Bar Association,

Presented at Current Issues in Toxic Torts and Product Liability, on October 18, 2007.

Speaker, Representing Mesothelioma Victims, Environmental Information Association, Las Vegas, Nevada 2007.

Author/Speaker, Ethics for Plaintiff’s Lawyers, NBI Seminar, Seattle, WA December 17, 2010.

Author/Speaker, Motions Practice, Superior Court Boot Camp, Seattle, WA, March 11, 2011.

Speaker, Medicare Reimbursement Issues—Demystifying Medicare, Plaintiffs Asbestos Litigation Seminar, Las Vegas, Nevada, May 13, 2011.

Memberships
Multnomah Bar Association
Washington State Bar Association
Tacoma-Pierce County Bar Association
Oregon Bar Association
Innocence Project Northwest
American and Washington State Associations for Justice

Recognition
Pro Bono Award, National Law Journal, 2000
Innocence Project Northwest
Quiet Hero Award, King County Bar Association, 2001
Washington Law & Politics, Super Lawyer, 2000 – 2005, 2010 – 2011

Military
Soldier of the Year, U.S. Army Support Command Hawaii
U.S. Army Support Command Hawaii, 1986-1988


Source:
- Law firm Bergman Draper Ladenburg, PLLC

National Cancer Research Month

Declared by the US Congress in 2007 and 2011, the American Association for Cancer Research, Philadelphia acknowledges May as National Cancer Research Month, in recognition of quality, innovative cancer research.

These two resolutions support efforts of the American Association for Cancer Research to facilitate progress and speed translation of latest scientific discoveries for the benefit of cancer victims and also the twelve million cancer survivors living in US today.

Watch video of Judy Garber, M.D., M.P.H., Past-president of American Association for Cancer Research, where she tells why cancer researchs is so important.

Some of research institutions, cancer centers, hospitals, advocacy groups, scientific societies, and other organizations that support National Cancer Research Month:

• American Society for Clinical Oncology
• American Society of Hematology
• American Society of Preventive Oncology
• American Society for Radiation Oncology
• Abramson Cancer Center of the University of Pennsylvania
• American Cancer Society Cancer Action Network
• American Childhood Cancer Organization
• American College of Radiology
• Association of American Cancer Institutes
• Arizona Cancer Center
• Barbara Ann Karmanos Cancer Institute
• Cancer Prevention Institute of California
• Cancer Therapy & Research Center, UT Health Science Center San Antonio
• Caring for Carcinoid Foundation
• Case Comprehensive Cancer Center
• C-Change
• City of Hope
• Cleveland Clinic Taussig Cancer Center
• Coalition of Cancer Cooperative Groups
• Dana-Farber Cancer Institute
• Duke Cancer Institute
• Fight Colorectal Cancer
• Fox Chase Cancer Center
• Fred Hutchinson Cancer Research Center
• Friends of Cancer Research
• Genetic Research Institute of the Desert
• Georgetown Lombardi Comprehensive Cancer Center
• Hollings Cancer Center
• Huntsman Cancer Institute
• Indiana University Melvin and Bren Simon Cancer Center
• International Cancer Advocacy Network
• International Myeloma Foundation
• Kimmel Cancer Center at Jefferson, Thomas Jefferson University and Hospitals
• Leukemia & Lymphoma Society
• Lustgarten Foundation
• Lung Cancer Foundation of America
• Lymphoma Research Foundation
• Mary Babb Randolph Cancer Center
• Massachusetts General Hospital Cancer Center
• Melanoma Research Alliance
• Memorial Sloan-Kettering Cancer Center
• Moffitt Cancer Center
• National Brain Tumor Society
• National Cancer Institute
• National Coalition for Cancer Research
• Norris Cotton Cancer Center
• North Carolina Central University
• OHSU Knight Cancer Institute
• Oncology Nursing Society
• OSU Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute
• Pancreatic Cancer Action Network
• Penn State Hershey Cancer Institute
• Prostate Cancer Foundation
• Robert H. Lurie Comprehensive Cancer Center
• Roswell Park Cancer Institute
• Sanford-Burnham Medical Research Institute
• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
• Society of Gynecologic Oncology
• Stand Up To Cancer
• Stanford Cancer Center
• St. Jude Children's Research Hospital
• Susan G. Komen for the Cure® Advocacy Alliance
• The Cancer Institute at NYU Langone Medical Center
• The Cancer Institute of New Jersey
• The Carole and Ray Neag Comprehensive Cancer Center
• The Jackson Laboratory
• The Leukemia & Lymphoma Society
• The University of Chicago Comprehensive Cancer Center
• The University of Kansas Cancer Center
• The UNMC Eppley Cancer Center
• The University of Texas MD Anderson Cancer Center
• The V Foundation for Cancer Research
• The Wistar Institute
• UAB Comprehensive Cancer Center
• UAMS Winthrop P. Rockefeller Cancer Institute
• UCLA's Jonsson Comprehensive Cancer Center
• UCSF Helen Diller Family Comprehensive Cancer Center
• UC Cancer Institute and the Barrett Cancer Center
• UC Davis Cancer Center
• UCI Chao Family Comprehensive Cancer Center
• University of Colorado Cancer Center
• University of Florida Shands Cancer Center
• University of Hawai'i Cancer Center
• University of Illinois at Chicago Cancer Center
• University of Iowa Holden Comprehensive Cancer Center
• UK Markey Cancer Center
• University of Maryland Marlene and Stewart Greenebaum Cancer Center
• University of Michigan Comprehensive Cancer Center
• University of New Mexico Cancer Center
• UNC Lineberger Comprehensive Cancer Center
• University of Pittsburgh Cancer Institute
• USC Norris Comprehensive Cancer Center
• University of Virginia Cancer Center
• Vanderbilt-Ingram Cancer Center
• Vermont Cancer Center
• Yale Cancer Center

Please email tara.yates@aacr.org., if you want to support National Cancer Research Month.

Asbestos exposure - how asbestos fibres damage lung tissue and lead to mesothelioma cancer

Asbestos is a heat-resistant mineral that was added to the building materials of many older homes for insulation, also to the clutches, brake linings, fire blankets, roofing shingles, etc...

To homeowners and workers who demolish or renovate those homes, asbestos fibers can pose health hazards. This short video shows how asbestos fibers could damage human lung tissue and lead to mesothelioma cancer.

Asbestos Mesothelioma Compensation Reform Delay in UK

After lobbying from Barrow and Furness MP John Woodcock, victims of the asbestos mesothelioma cancer will initially be exempt from a government's reform to no-win, no-fee legal claims.

The UK government last week angered lords, campaigners and MPs by including victims of the industrial disease in changes which will see successful claimants pay part of their damages to their solicitors (lawyers).

The UK government said the changes were designed to discourage spurious claims, but Mr John Woodcock and other MPs argued asbestos mesothelioma victims should be exempt as a result of the severity of this disease.

Mr. Jonathan Djanogly, justice minister, said there had been careful reflection concerning the sensitivity of the cases of mesothelioma victims.

Mr. Djanogly also said the planned changes wouldn't be introduced for mesothelioma compensation next April but the latter will be.

Mr John Woodcock said: “The UK government proposals on asbestos mesothelioma cases were breathtaking in their lack of sensitivity and arrogance. Mesothelioma cancer is a deadly disease, which hundreds in Barrow and Furness suffer from as a result of their work in the ships building that defended our shores."

"They deserve every penny of mesothelioma compensation they're awarded." said Woodcock "To lump them in as part of a ‘compensation culture’ is absurd!"

Mr. Woodcock also said: “I am pleased that, following their defeat in the crossbench peers and Lords by Labour, ministers finally provide grounds to this issue. Mesothelioma cancer victims will now be excluded from the Jackson reforms to legal aid, which would have seen the costs of their mesothelioma cases being deducted from their compensation. UK ministers have committed to only implementing any changes following a review by the Lord Chancellor into their possible impact on mesothelioma proceedings. We clearly still have to be vigilant, because the threat of docking compensation has not entirely gone away, however i'm happy that we've at least secured this pause.”

Since 1981, from the mesothelioma cancer, 197 victims in Barrow and Furness, 42 victims in Copeland and 59 victims in South Lakeland have died, according to figures from the HSE (Health and Safety executive). Health and Safety executive is the national independent watchdog for work-related safety, health and illness.

If you or a loved one has been recently diagnosed with mesothelioma cancer, you can file a mesothelioma lawsuit. Find experienced law firm and/or mesothelioma attorneys in our directory or look some of experienced asbestos lawyer profiles.

New hope - Drug Sorafenib well tolerated

British investigators report, the sorafenib, which is also known as nexavar, is well tolerated in patients with mesothelioma cancer when they complete platinum-containing chemotherapy.

Sorafenib (nexavar) is a a multi-targeted kinase inhibitor. It works by slowing the growth of new blood vessels within the tumour mass. Sorafenib also hinders the growth of some types of malignant cells.

In a trial (phase II) of sorafenib (nexavar) following first-line chemotherapy in fifty three patients with mesothelioma cancer, thirty fourth of patients were progression-free after 6 months.

Dr James Spicer and Dr Sophie Papa from Kings college, London, United Kingdom and colleagues say that the sorafenib was well tolerated and offered a length of progression-free survival that "compares favorably" to some other targeted agents in this rare disease.

From the Department of Thoracic Oncology, The Netherlands Cancer Institute, Professor Paul Baas (email: p.baas@nki.nl) said: "Mesothelioma cancer is one of the most important occupational diseases. It begins to attract a lot of attention these days. Recent developments in the treatment and diagnostics of this rare disease are very important together with those presented in the ELCC 2012 meeting: improvements in the diagnosis by simply measuring biomarkers in peripheral blood samples can identify patients who can be candidates for brand new studies or financial reimbursement by their employers. Molecular biology new developments now allow us to detect circulating fragments of peptides and (micro)RNA which can play a very important role. Furthermore the understanding that targeted agents and radiation therapy may be given to those patients can result in new, promising, studies."